Ru 486 Misconceptions Myths and Morals - ressourcesfeministes

More documents

Recommendations

Info

The History of RU 486pharmacovigilance network alerted the Ministry of Healthto the death of a woman from chemical abortion. On 8 April1991, the Ministry of Health issued a Communiqué stating thata 31-year-old woman had died from cardiovascular shock(heart failure) shortly after an injection of the prostaglandinNalador (sulprostone) in conjunction with Myfégyne (RU486). The first of ‘a few catastrophes’ had taken place, not inthe third world but in high-tech France, where the safetyrequirements in case of emergency (e.g. equipment,medications) should have been met. Few details werereleased, but the Communiqué did point out that the youngwoman was a heavy smoker and in her 13th pregnancy (othersources mentioned that she was the mother of 11 children),and that in 1990, the Ministry of Health had warned againstthe use of RU 486/PG by smokers. Roussel Uclaf alsorevealed that the prostaglandin Nalador used independentof RU 486 was implicated in the deaths of three other womenand four additional women who had suffered non-fatal heartattacks (quoted in Riding, 1991).The company’s response to the RU 486/Nalador deathwas simple: switch to another prostaglandin—gemeprost—which, although administered as a vaginal suppositoryrequires increasing the dosage significantly from 0.25 mg to1 mg (idem., see also Chapter Four). On 19 April, the HealthMinistry ruled that RU 486/PG was not to be administeredto women who have smoked for more than two years or areolder than 35. Further, it had decided to reduce the dosageof Nalador to 0.125 mg or alternatively to use 1 mg ofCervagem (gemeprost), and also mentioned that oralprostaglandin administration was under investigation.Rather than expressing distress and bewilderment overthe woman’s death, Baulieu on the same day announced hislatest experiments with women using an oral prostaglandin.As he put it, the oral prostaglandin was ‘simpler,…lesspainful and possibly safer’ than his previous promise forsafe and effective abortion (Altman, 1991: C3; but see also23
RU 486Chapter Four for adverse effects of misoprostol). 18 Whenasked in a telephone interview when he first became awareof the dangers of Nalador (sulprostone) on Radio National,Australia, Baulieu’s reply was, ‘about three weeks ago’(Delaney, 22 April 1991)!24
Page 2 and 3: Renate Klein is Lecturer in Women
Page 4 and 5: RU 486Misconceptions,Myths and Mora
Page 6 and 7: ACKNOWLEDGEMENTSWe would like to ex
Page 8 and 9: CONTENTSINTRODUCTION 1CHAPTER ONETh
Page 10 and 11: INTRODUCTIONInitial euphoria greete
Page 12 and 13: IntroductionUnfortunately, objectio
Page 14 and 15: Introductiondo not know or do not a
Page 16 and 17: Introductionused widely for years a
Page 18 and 19: CHAPTER ONEThe History of RU 486RU
Page 20 and 21: The History of RU 486consultants ar
Page 22 and 23: The History of RU 486Events in Fran
Page 24 and 25: The History of RU 486service of wom
Page 26 and 27: The History of RU 486The result app
Page 28 and 29: The History of RU 486developing cou
Page 30 and 31: The History of RU 486University Hos
Page 34 and 35: CHAPTER TWOClaims for RU 486/PG Abo
Page 36 and 37: Claims for RU 486/PG Abortionsevera
Page 38 and 39: Claims for RU 486/PG Abortionthe Br
Page 40 and 41: Claims for RU 486/PG Abortionan imm
Page 42 and 43: Claims for RU 486/PG Abortionby the
Page 44 and 45: Claims for RU 486/PG Abortionby the
Page 46 and 47: Claims for RU 486/PG Abortionfrom A
Page 48 and 49: Claims for RU 486/PG Abortioncommen
Page 50 and 51: Claims for RU 486/PG AbortionSome s
Page 52 and 53: Claims for RU 486/PG Abortionbreeze
Page 54 and 55: Claims for RU 486/PG Abortion18 per
Page 56 and 57: Claims for RU 486/PG Abortion1. RU
Page 58 and 59: Claims for RU 486/PG AbortionRU 486
Page 60 and 61: Claims for RU 486/PG Abortionwider
Page 62 and 63: Claims for RU 486/PG Abortionmedica
Page 64 and 65: Claims for RU 486/PG Abortionreligi
Page 66 and 67: What Is RU 486 and How Does It Work
Page 82 and 83:
What Is RU 486 and How Does It Work
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
The Role of Prostaglandins: Known a
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
ConclusionInstead, Baulieu uses the
Page 124 and 125:
Conclusionintervention. Thus, RU 48
Page 126 and 127:
Conclusionbetween population contro
Page 128 and 129:
ConclusionThis article, appearing i
Page 130 and 131:
Conclusion‘a whole net of relatio
Page 132 and 133:
ENDNOTESChapter One1The paten t lic
Page 134 and 135:
Endnotes12The Journal Officiel publ
Page 136 and 137:
Endnotesin Gynecology and Obstetric
Page 138 and 139:
Endnotesof menses. On the third day
Page 140 and 141:
EndnotesAnother such example is the
Page 142 and 143:
Bibliographyand Segal, Sheldon (Eds
Page 144 and 145:
Bibliographyprostaglandin F 2•. A
Page 146 and 147:
BibliographyDelaney, Anne. (1991, 2
Page 148 and 149:
Bibliographyresponses to the steroi
Page 150 and 151:
Bibliographyabnormalities resulting
Page 152 and 153:
Bibliographyprogesterone receptor b
Page 154 and 155:
BibliographyOdlind, Viveca and Birg
Page 156 and 157:
BibliographyBinding of the anti-pro
Page 158 and 159:
BibliographyUlmann, André, Teutsch
Page 160:
Bibliographytermination by vacuum a
show all

Ru 486 Misconceptions Myths and Morals - ressourcesfeministes

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?